Method for correcting cytolytic syndrome in chronic hepatitis cases

FIELD: medicine.

SUBSTANCE: method involves administering Corbiculin at a dose of 2 g three times a day when prediluted with 50 ml of water. The treatment course is 21 days long or longer until alanine aminotransferase and aspartate aminotransferase indices assume normal values.

EFFECT: enhanced effectiveness in normalizing hyperenzymemia and relieving clinic manifestations of cytolytic syndrome.

2 tbl

 

The invention relates to medicine and can be used for functional recovery of the liver in chronic hepatitis infectious and non-infectious origin.

It is known that pathological processes in the liver, with various acute and chronic diseases are accompanied by cytolytic syndrome, i.e. a violation of the structure and function of membrane systems of hepatocytes. Its progression can lead to decompensation of vital functions of the liver. Special attention should be paid to the group of chronic diffuse hepatitis, in which, in contrast to acute processes develop destructive inflammatory changes in the liver parenchyma occurring as an independent disease and therefore require differentiated treatment. They can be both communicable and non-communicable nature.

Syndrome integrity of hepatocytes (cytolysis syndrome) characterized by an increase in plasma activity of indicator enzymes - AST, Alt, LDH and isoenzymes - LDH and LDH specific liver enzymes: fructose-1-hospitalilty, sarbadhikari, as well as the concentration of ferritin, serum iron, vitamin B12 and bilirubin mainly due to increase direct fraction. In assessing the severity of the pathological process, the main value in the highlighted activity of Alt and AST. The higher their level in blood serum is less than 5 times compared with the upper limit of normal is considered as a moderate, 5 to 10 times as the average degree and over 10 times as high severity of the inflammatory process in the liver. Morphological basis of this syndrome are hydropic and acidophilic degeneration and necrosis of hepatocytes from damage and increased permeability of cell membranes.

Despite the diversity of etiologic factors in chronic liver diseases on the cellular level revealed similar mechanisms of degradation, among which a special role is played by the free-radical oxidation processes involving reactive oxygen species. In recent work it was shown that the intensification of the processes of free radical oxidation of lipids, on the one hand, and reduced activity of the antioxidant system, on the other hand, are essential for the formation of cytolysis [2, 4]. Therefore, one of the most important problems of modern medicine is the use of drugs that have system-wide effect and has membrane stabilizing and antioxidant properties. Such drugs membranostabiliziruyuschee and antioxidant action, as glucocorticosteroids, ascorbic acid, cytochrome C, quercetin, found only limited applications to the interview. While they give a lot of side effects and recommended antioxidants (ascorbic acid, cytochrome C, quercetin, represent only askarruttavista (water-soluble) link antiradical protection system cells.

Hepatoprotective effect has Heptral, Phosphogliv [3, 6]. However, their appointment requires the observance of the regimen of administration of the drug in the form of intravenous infusions, and then oral intake, which creates inconvenience for outpatient treatment [7, 8].

Drugs Kars, legal, hepatophilic containing the extract of the fruit of the plant, milk Thistle, and essential phospholipids possess hepatoprotective and antioxidant effects. However, the effectiveness of these drugs in controlled clinical studies using control liver biopsies done in early Scandinavian, and then in European hospitals, did not confirm the expected positive result (Thaler N., 1983, is quoted in Argetnina, 1994). These drugs can lead to increased activity of transaminases and to the emergence or strengthening of cholestasis [1, 5].

Thus, for practical health remains the task of finding new, more effective means, is able to accelerate functional in the formation of the liver or to protect the hepatocytes from the damaging effects of hepatotropic viruses and other pathogens.

The objective of the invention is to develop an effective method for correcting cytolytic syndrome. The problem is solved by assigning Corbicula 2 g orally 3 times a day after meals, pre-dissolved in water.

Corbicula - preventive food product (RF patent No. 2219805, IPC A 23 L 1/30)with hepatoprotective and antioxidant effect.

As shown by analysis of the available scientific and patent information, information relating to the use of Corbicula, for the correction of cytolytic syndrome with chronic hepatitis infectious and non-infectious origin not found.

The study included 35 patients aged from 18 to 62 years. In the study group included 20 patients in the control and 15. Patients in both groups are comparable in sex, age, nosological forms and severity of the disease and received a standard basic therapy in the form of diet regime, complex detoxification activities (drinking plenty of fluids, intravenous 5% glucose solution 500 ml or ingestion of interdata, rehydron within 7-10 days). In the group included the patients with chronic hepatitis of different etiology: 20 - with viral hepatitis b and C (57%), 8 with alcoholic liver disease (23%), 4 with non-alcoholic steatohepatitis (11%), 3 - with compensated liver cirrhosis (alcoholic and viral e is eologie) (9%). For the correction of cytolytic syndrome patients from the main group assigned Corbicula 2 g three times a day after meals, pre-dissolved in 50 ml of water prior to normalization of liver enzymes (Alt and AST). Patients of the control group as hepatoprotective therapy received Carsil 2 tablets 3 times a day. Criteria of effectiveness of the drug are: the dynamics of subjective complaints (severity major klinichnih syndromes) and assessment of the General condition of the patient in points, the degree of recovery of liver function according to laboratory (functional liver function tests) and instrumental (ultrasound of the abdominal cavity) studies. Evaluation of the clinical and laboratory data is carried out before and after a course correction cytolytic syndrome. The effectiveness of the study drug is evaluated on the basis of the above criteria according to the following scale: poor - absence of clinical improvement, deterioration, conservation signs of activity of the process; satisfactory clinical improvement, reduction of activity, the preservation of the signs of activity of the process; good - noticeable clinical improvement, disappearance of signs of activity and significant improvement in biochemical parameters.

Data from clinical and laboratory research process is Statisticheskii generally accepted in medicine methods of variation statistics. In all patients before surgery hepatoprotective drugs noted complaints about the feeling of heaviness and re-dull pain in the right hypochondrium in 69% of cases (24 people), often without any irradiation in 14% of cases (4 persons)arising after errors in diet, at least - after negative emotions in 6% of cases (2 people), a feeling of bitterness in the mouth in 71% of cases (25 people), podtashnivaet in 57% of cases (20 people). Objective examination revealed Palmar erythema in 23% of patients (8 persons), subikterichnost sclera in 43% of patients (15 people), mild tenderness in the right hypochondrium, 71% of patients (25 people). Dyspeptic syndrome combined with vegetativnymi disorders: weakness, fatigue, unstable sleep, irritability in 63% of cases (22 people). Hepatomegaly was detected in 25% of cases, splenomegaly is 15%.

Dynamics of the main clinical syndromes in the groups are presented in table 1. As can be seen from the table, after 3 weeks in the study group was significantly compared with the control group also noted the disappearance of weakness, heaviness in the upper abdomen, the disappearance of nausea, appetite improved in 90% of patients (18). 25% of patients (5 people) there was a decrease in the size and density of the liver.

40% (6 persons)
Table 1
Dynamic is and clinical symptoms in patients with hepatitis on the background correction cytolytic syndrome in different ways
Clinical syndromeThe main group (n=20)Control group (n=15)
Before adjusting CorbiculaAfter the correction CorbiculaBefore adjusting the KarsAfter correction of the Kars
Pain in the right hypochondrium:
- dull, aching, long70% (14 persons)5% (1 person)*80% (12 persons)40% (6 persons)
without irradiation10% (2 persons)020% (3 persons)20% (3 persons)
- short-term10% (2 persons)5% (1 person)20% (3 persons)10% (2 persons)
Nausea, belching65% (13 persons)10% (2 people)*70% (11 people),the50% (8 persons)
The feeling of bitterness in the mouth75% (15 persons)15% (3 respondents)*70% (11 persons)40% (6 persons)
Weakness, fatigue90% (18 persons)10% (2 people)*90%(14 persons)40% (6 persons)
Loss of appetite80% (16 persons)10% (2 people)*80% (12 persons)
Hepatomegaly45% (9 persons)25% (5 persons)*40% (6 persons)40% (6 persons)
* - P<0,05 compared with the control group differences authentic

In the study of biochemical parameters in most patients with HG source revealed increased activity of Alat and thymol turbidity tests, symptoms of intrahepatic cholestasis (hyperbilirubinemia, increased activity of betalipoprotein and the activity of Alp (alkaline phosphatase)). As can be seen from table 2, the patients of the main group receiving Corbicula, after 3 weeks, normalization of bilirubin, thymol turbidity tests, GGT, cholesterol. These indicators in the control group tended to decrease, but the rate did not fit. The level of Alt was decreased in both groups, but in the main group, where used Corbicula, after 3 weeks there was normalization of the studied parameters compared with the control group, where the normalization did not occur. Analysis of all these changes gave the basis to assess the results of the correction of cytolytic syndrome as good in 25 patients (71%) and satisfactory in 10 patients (29%).

Table 2
Dynamics of biochemical indices in patients with hepatitis in the background to correct them in different ways
Indicators biochemistry of bloodGroup to correctionGroup after correction
MainControlMainControl
Bilirubin (mol/l)33,3±3,932,6±3,618,5±1,8*25,8±2,2
Alt (ľkat/l)1,4±0,61,5±0,40,9±0,2*1,3±0,2
Thymol turbidity test (ed)5,9±1,05,3±0,93,7±0,5*4,8±1,1
GGT (me/l)71,2±35,568,8±29,555,2±19,5*6,8±20,1
Alkaline phosphatase (me/l)86,2±26,388,9±20,375,7±24,5*85,0±21,5
Cholesterol (mol/l)5,1±0,125,5±0,34,8±0,3*5,3±0,4
The main group (n=20) - correction Corbicula
Control group (n=15) - correction of the Kars
* the degree of reliability of the data differences compared with the control group (P<0,05)

Drug Corbicula was well tolerated by the patients, side effects, its use is not marked.

Example 1. Patient A., 37 years. Hurts hepatitis b and C since 1999, Asked for a consultation with complaints of weakness, weakness, paleness of skin and yellowing of the sclera, and recurrent pain in the right hypochondrium. Blood bilirubin total - 57.5 mmol/l, direct - to 27.0 mmol/l, indirect - to 30.5 mmol/l, the activity of ASAT - of 693, 3 u/l, Alat - 1319 IU/L. Appointed Corbicula order correction syndrome cytolysis within 21 days (2 g, 3 times a day after meals, pre-dissolved in water). When you re-inspection within a week after receiving Corbicula - continued complaints only on rare pressing pain in the right hypochondrium. Paleness of skin and mucous membranes, weakness, yellowing of the sclera disappeared. Blood bilirubin total - 22,0 mmol/l associated - 13 mmol/l, the level of Alat - 35 u/l, AST - 40 IU/l Is within 9 months of follow-up. The condition is not getting worse.

Example 2. Patient B., 46 years old. Sick With hepatitis C about 2 years. Previously used drugs, was taking a course in narcological dispensary. When the treatment complained of nausea, bitter taste in the morning in the mouth, weakness, heaviness in the right poreber is e, epigastric discomfort. On ultrasound hepatomegaly with diffuse changes of a liver and signs of cirrhosis. During examination:

IndicatorsResults studies
24.120212.01.0320.01.03
The total bilirubin (mol/l) -59,018,0of 17.0
Bilirubin is associated (mol/l)39,025,0to 12.0
Thymol turbidity test (units)854
Alt (units/l)175,093,036
AST (units/l)136,9100,540,2
Alkaline phosphatase (units/l)240,7112,754,0
GGT (units/l)176,990,566,9

The patient was appointed the inventive correction of cytolytic syndrome (reception Corbicula 2 g 3 times a day after meals, pre-dissolved in water). The course of therapy was 56 days. Tolerability was good, without complications. Biochemical parameters and General condition of the patient improved (disappeared nausea, bitter taste in the mouth, periodic Bo is in the right hypochondrium). The patient is on a dynamic outpatient observation. In the autumn of conducted maintenance therapy Corbicula (2 g, 3 times a day for 14 days).

Example 3. Patient A., aged 40. Obese II century, non-alcoholic steatohepatitis. Complained of heaviness in the right hypochondrium, weakness, nausea and a bitter taste in the mouth. When examining activity detected Alat-4N, ASAT-2N, bilirubin increased due to the direct fraction to 43.9 mmol/L. When ultrasound signs of fatty hepatosis. Markers of viral hepatitis negative. After taking Corbicula orally 2 g 3 times a day after meals, pre-dissolved water, within 21 days marks a significant improvement in well-being: disappeared weakness, nausea, bitter taste in the mouth. Biochemical parameters during the control study were within normal limits.

Thus, when the appointment for the correction of cytolytic syndrome drug Corbicula installed its high clinical efficacy in patients with chronic hepatitis of different etiology. Corbicula has good portability, none of the 20 patients treated with the drug at a dose of 2 g 3 times a day after meals, pre-dissolved in water, not noted any side effects and allergic reactions. The proposed correction method allows to effectively work on pathological symptoms Zab the diseases, to neutralize HyperTerminal. He successfully can be used for conservative and outpatient correction cytolytic syndrome broad range of patients with chronic diffuse liver diseases.

Sources of information

1. Aprosyn SG // Klin. the honey. - 1984. No. 9. - P.27-32.

2. Nikitin E.V. Clinical and pathogenetic status of lipid peroxidation and enzymatic antioxidant system in patients with viral hepatitis b: Thesis ... Dr. med. Sciences. - Odessa, 1990. - 278 S.

3. Podymova S.D., Naginsky M. evaluation of the efficacy of Heptral in patients with chronic diffuse liver disease with cholestasis // Clinical medicine. - 1998. No. 10. - P.45-48.

4. The roller N, Smania CENTURIES, Ohrimovich L.M. Clinical pharmacology hepatoprotectors. - Ternopil, 1995. - 272 S.

5. Sorenson S.N. Viral hepatitis. - L., 1987.

6. Stroganov of GI, I.E. science, Nikitin I.G. and other Theoretical and practical aspects of the use of glycyrrhizin // prospects of Clinical gastroenterology, Hepatology. - 2003. No. 1. - P.35-39.

7. Van Rossum THUS, A.G. Vulto, Hop W.Q, Schalm S.W. Glycyrrhizzinn-Induced reduction of ALT in European patient With chronic hepatitis // Am.J.Gastroenterol. - 2001. - Vol.96. No. 8. - P.2432-2437.

8. Yamamura Y. et al. The phamacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbontetrachloride intoxicated rats // Biopharm drag Dispos. - 1997. - Vol.18. - P.717-772.

The method for correcting cytolitic the ski syndrome in chronic hepatitis, including hepatoprotective drug, characterized in that designate Corbicula 2 g 3 times a day after meals, pre-dissolved in 50 ml of water course of 21 days or more prior to normalization of Alt and AST.



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new N-acylated pseudodipeptides comprising acidic group in neutral or charged form by one end of pseudodipeptide and accessory functionalized branching by the opposite end and corresponding to the general formula (I): wherein each R1 and R2 means acyl group of saturated or unsaturated, linear or branched carboxylic acid comprising from 2 to 24 carbon atoms, unsubstituted or comprising a substitute or substitutes chosen from hydroxyl, alkoxy- and acyloxy-groups; coefficient n has values from 0 to 3; coefficients p and q have values from 1 to 3; coefficient m has values from 1 to 3 except for a case when X means carboxyl or one of its derivative, and in this case it means values form 0 to 3; Y means oxygen atom (O) or -NH; X and Z mean accessory functionalized branching or acidic group in neutral or charged form chosen from the following groups: carboxyl, carboxy-(C1-C5)-alkoxy-, carboxy-(C1-C5)-alkylthio-, phosphono-(C1-C5)-alkoxy-, dihydroxyphosphoryloxy-, hydroxysulfonyloxy-, (carboxy-(C1-C5)-alkyl)aminocarbonyl, (dicarboxy-(C1-C5)-alkyl)aminocarbonyl, (ammonio-(C1-C5)-aminocarbonyl, carboxy-(amino-(C1-C5)-alkyl)aminocarbonyl under condition that at least one substitute among X and Z means an accessory functionalized branching, and their enantiomers and diastereoisomers. Proposed compounds show immunomolulating properties as adjuvants and these compounds can be grafted to antigen to modulate the immune response or can be grafted to pharmacophore to improve the therapeutic effect or its directed delivery.

EFFECT: improved preparing methods, improved and valuable medicinal properties of substances and compositions.

48 cl, 3 tbl, 112 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: method involves applying antiherpetic therapy using Phamcyclovir. Then, Trental is sequentially introduced during 5 days with 2-5 ml of cerebrolysin being concurrently intratissularly introduced behind mastoid process tip. Mexidol is administered for 10 days. The treatment is finished by introducing Polyoxydonium.

EFFECT: combined microcirculation improvement; high neurotrophic and antioxidant activity; secondary immune deficiency adjustment; eliminated labyrinth hydrops.

FIELD: veterinary science.

SUBSTANCE: method involves using the preparation "Furatsiklin M" in the dose 0.5 g/kg of living mass with additional using the preparation "Immunobak" as 3 doses per a head. Preparations are administrated in chickens of age 120, 140 and 300 days by oral route, 2 times per 24 h, for 5 days by three courses. Method promotes to effective neutralization of the disease pathogen, enhanced resistance of chicken body and recoveries biocenosis after termination of treatment. Invention can be used in treatment of mycoplasmosis in chickens.

EFFECT: improved and enhanced effectiveness of treatment.

12 tbl, 2 ex

FIELD: veterinary science.

SUBSTANCE: invention involves the combined use of antibacterial preparations and immunomodulator. Method involves complex of single and double RNA sodium salts from killer yeast Saccharomyces cerevisiae as an immunomodulator and synthetic polymer-carrier taken in the dose 0.3-0.4 mg/kg. Immunomodulator is administrated in animals in a single dose before onset of critical period, i. e. in 15-20 days of piglets growing. Method provides stimulation of factors of cellular and humoral immunity of animals without adverse reactions and complication due to selection of optimal dose of immunomodulator and its prolonged effect.

EFFECT: improved method for treatment and prophylaxis.

3 cl, 4 tbl, 3 ex

FIELD: medicine, pediatrics, pulmonology, allergology.

SUBSTANCE: method involves administration of viferon by rectal way. Viferon-1 is dosed to children of age 3-6 years (150000 IU in one suppository), and viferon-2 is dosed to children of age 7-14 years (500000 IU in one suppository) every day, twice per a day, for 10 days and then for 4 weeks in every other day. Proposed invention promotes to decrease numbers of bronchial asthma exacerbation, diminishing degree of bronchial asthma severe attack, decreasing frequency of bronchial asthma, increasing period of bronchial asthma remission due to activation of the interferon system. Invention can be used in treatment of bronchial asthma in children suffering from ARVI often and/or for a long time.

EFFECT: enhanced effectiveness of treatment.

6 tbl, 3 ex

FIELD: pharmaceutical industry, in particular immunomodulating agents and production of pharmaceutical compositions containing the same.

SUBSTANCE: claimed immunomodulating agent represents complex of monosulfated cucumariosides with sterol in molar ratio cucumariosides/sterol of 1:2. Said complex is obtained by addition of sterol solution to extract from Cucumaria japonica, or extract of wastewater from Cucumaria japonica processing, or cucumarioside solution. As sterol solution cholesterol or sitosterol. Pharmaceutical composition having immunomodulating activity contains abovementioned agent and filler in specific component ratio.

EFFECT: non-toxic pharmaceutical composition useful as tumor inhibitory agent.

4 cl, 11 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: one should carry out antibacterial and infusion therapy. Moreover, additionally, after compensating the volume of circulating blood during infusion therapy one should intravenously inject 30 thousand IU antigangrenous polyvalent equine serum by drops per 200 ml isotonic NaCl solution: the first 1 ml solution should be injected for 5 min, the rest volume - for 1-1.5 h. The innovation suggested enables to optimize immunocorrecting therapy without sensitizing patient's body.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

FIELD: pharmaceutical industry, in particular drug containing human recombinant alpha-2 interferon.

SUBSTANCE: claimed prolonged solution contains human recombinant alpha-2 interferon, citric acid, boric acid, sodium tetraborate, unithiol, human serum albumin, sodium chloride, sodium carboxymethylcellulose and purified water. Preparation of present invention has wide spectrum of therapeutic application.

EFFECT: drug of high specific antiviral and antimicrobial activity without side effects.

1 tbl, 3 ex

FIELD: medicine, pediatrics.

SUBSTANCE: in small children at syndrome of increased thymus gland degree 1-3 one should prescribe prednisolone and eubiotics simultaneously, and at degree 2-3 it is necessary to prescribe immunomodulating agents, additionally. The innovation provides increased anti-infectious immunity and inspecific body resistance due to efficient correction of hormonal state in this group of children.

EFFECT: higher efficiency of prophylaxis.

2 cl, 1 ex

FIELD: veterinary obstetrics.

SUBSTANCE: the method deals with subcutaneous injection of bioglobin (placenta denaturated suspended - PDS) at the quantity of 20 mg/animal/d not earlier that 10 d before calving. The innovation enables to increase quality in preventing the onset of functional dyspepsia in newborn calves and level of total body resistance.

EFFECT: higher efficiency.

20 dwg, 1 ex, 2 tbl

FIELD: medicine, hepatology.

SUBSTANCE: the present innovation deals with treating hepatitis and hepatic cirrhosis of different etiology. For this purpose, in case of viral hepatitis B and C at the stage of active viral replication one should inject sodium hypochlorite solution into central vein at concentration of 300-600 mg/l at the rate of 60 drops/min, per about 200-400 ml every other day, about 5-7 procedures/course; in case of viral hepatitis B and C beyond the stage of active viral replication one should inject sodium hypochlorite solution into peripheral vein at concentration of 300 mg/l at the rate of 30 drops/min per about 200-400 ml every other day, about 5-7 procedures/course; in case of hepatitis of non-viral etiology one should inject sodium hypochlorite solution into peripheral vein at concentration of about 200-300 mg/l at the rate of 30 drops/min, per about 200-400 ml daily, about 3-5 procedures/course; in case of hepatic cirrhosis it is necessary to inject sodium hypochlorite solution into peripheral vein at concentration of about 100-200 mg/l at the rate of 40 drops/min, per about 200-400 ml every other day, about 3-5 procedures/course. The innovation suggested provides increased efficiency of detoxication and anti-viral impact due to differentiated matching both the dosages and modes of preparation injection at different forms of hepatic lesions.

EFFECT: higher efficiency of therapy.

2 ex, 1 tbl

FIELD: medicine, gastroenterology, phytotherapy.

SUBSTANCE: invention relates to the development of agent used in treatment of stomach and duodenum ulcer disease with eradication of microorganism Helicobacter pylori occurring on the background of liver chronic diseases. Agent represents a species of medicinal plants and comprises common milfoil, fenestrate Saint-John's-wort, medicinal matricary, sweet flag rhizome with roots, common wormwood, sandy immortelle, black elder flowers, medicinal pot-marigold, peppermint, sage, dioecious nettle, umbellate centaury, medicinal sweet clove, medicinal dandelion roots, great burnet rhizomes, gum-tree leaves, tansy, maize stigmas, creeping thyme, cowberry leaves, flax seeds, tormentil rhizomes, linden flowers, common bear berry taken in the therapeutic dosage and in the definite mass ratio of components. The agent reduces the toxic effect of hepatobiliary system and prolongs the remission periods.

EFFECT: improved, enhanced and valuable medicinal properties of agent.

2 tbl, 4 ex

FIELD: medicine, pharmaceutical industry, phytotherapy.

SUBSTANCE: invention proposes an agent used in treatment of infectious diseases. Agent used in treatment of infectious diseases comprises chitosan of polyfraction composition with amine groups of molecular mass from monomeric link - glucosamine to ˜350 kDa and deacetylation degree from ˜68 to ≤ 95% and vegetable raw aqueous extract chosen from the following group: Cetraria thallus, sage official herb, cocklebur leaves, black poplar buds, common wormwood herb, red roots, burdock roots, French honey-suckle herb, bur-marigold tripartite herb, sandy common immortelle flowers, dropwort elm-leaved flowers, river avens (Geum) roots, licorice glabrous roots, swampy sweet flag roots, burnet official roots,, nettle dioecious herb, swampy cudweed herb, common milfoil herb, sweet clover official herb, gum-free leaves, dropwort, willow bark, birch leaves, bilberry leaves, willow-herb narrow-leaves herb, peppermint herb, fenestrate Saint-John's-wort herb, knot-grass herb, shepherd's purse herb, violet pensy tricolor herb, speedwell herb, pot-marigold flowers, common tansy flowers, matricary official flowers, chicory roots, dandelion official roots, tormentil roots, cinnamon wild rose fruits, viburnum leaves, pinnate kalanchoe and maize stigmas. Aqueous extract is prepared by extraction of vegetable raw with demineralized water under definite conditions. Agent promotes to effective treatment of infectious diseases, such as chlamydiosis, herpes, erysipelas, viral hepatitis A and B, gastroenteric tract diseases, acute enteric infectious, and to declining period of clinical symptoms of diseases said.

EFFECT: valuable medicinal properties of agent.

10 cl, 2 dwg, 12 ex

FIELD: medicine, hepatology, chemical-pharmaceutical industry, biotechnology.

SUBSTANCE: invention relates to a biotransplant used in treatment of chronic hepatitis and liver cirrhosis and comprising mesenchymal stem cells obtained from fetal or donor material. The parent tissue is subjected for disaggregation followed by culturing as fixed colonies in the growth medium containing fetal calve serum and glutamine and passage at low density value with change of medium composition and cultivation is carried out without accumulation cells with mature stroma in culture. Also, invention relates to a method for treatment of chronic hepatitis and liver cirrhosis that involves administration of indicated biotransplants by using venous catheter or by puncture in the portal system veins, or by using arterial catheter in splenic artery, or by puncture in spleen parenchyma, or by intraperitoneal route, or by puncture in gastrocolic omentum. Invention provides enhancing effectiveness in complex effect on damaged liver.

EFFECT: improved preparing method, improved treatment method.

13 cl

FIELD: medicine, oncology, biology.

SUBSTANCE: method involves per os administration of the preparation "oligokhit activ" to a cancer carrier in the dose 20-24 mg/kg of weight for 7 days, not less. Method provides elimination of dystrophic changes in hepatocytes caused by metabolic disturbances in body of a cancer carrier, to improve proliferative activity of hepatocytes and to recover microcirculation.

EFFECT: improved correction method.

1 tbl, 1 ex

FIELD: medicine, hepatology.

SUBSTANCE: invention relates to treatment of chronic hepatitis C. Method involves administration in a patient α2A-interferon modified with polyethylene glycol (PEG)(conjugate PEG-IFN-α2A) in combination with ribavirin. Method provides the prolonged clearance of virus that promotes both activity with respect to cells proliferation and effective treatment of disease.

EFFECT: enhanced effectiveness of preparation.

2 cl, 1 tbl, 1 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivative of triazaspiro[5.5]undecane of the formula (I): wherein R1 means compound of the formula (1): or (2): wherein G represents a bond, (C1-C4)-alkylene, (C2-C4)-alkenylene or -CO-; ring A represents: (1) C5-10-membered mono- or bicarbocyclic ring or (2) 5-10-membered mono- or bicyclic heterocycle comprising 1-2 nitrogen atoms and/or 1-2 oxygen atoms; substitute R6 means the following values: (1) (C1-C4)-alkyl, (2) halogen atom, (3) nitrile group, (4) trifluoromethyl group and others; R2 represents: (1) (C1-C4)-alkyl, (2) (C2-C4)alkynyl or (3) (C1-C4)-alkyl substituted with a substitute represented in claim 1 of the invention claim; each R3 and R4 represents independently: (1) hydrogen atom, (2) (C1-C4)-alkyl or (3) (C1-C4)-alkyl substituted with 1-2 substituted taken among: (a) Cyc 2 and (b) hydroxy-group (wherein Cyc 2 represents (1) C5-6-membered monocarbocyclic ring or (2) 5-6-membered monocyclic heterocycle comprising 1-2 nitrogen atoms and/or one oxygen atom), or R3 and R4 form in common group of the formula: wherein R26 represents (C1-C4)-alkyl or Cyc 2; R5 represents hydrogen atom or (C1-C4)-alkyl, its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to pharmaceutical composition inhibiting HIV, regulator of chemokine/chemokine receptor and agent used in treatment and prophylaxis of some diseases, such as inflammatory diseases, asthma, atopic dermatitis, nettle rash, allergic diseases, nephritis, hepatitis, arthritis and other diseases that comprise as an active component above described compound of the formula (I) or its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof, and to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane hydrochloride and pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of derivative and composition.

16 cl, 32 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with the ways of extracorporal detoxication and treatment of hepatic failure. The method should be implemented due to introducing albumin-containing solution through a catheter into abdominal cavity at concentration of 30-40 g/l as dialyzing liquid for 2-4 h. This solution should be purified through "Artificial kidney" apparatus, coal sorbent and anion-exchange resin. Perfusion rate of albumin-containing solution in the course of its purification corresponds to 20-30 ml/min. Detoxication cycle with the help of albumin followed by its deligandization should be repeated many times. The innovation provides optimal mode of perfusion and, thus, high rate of toxins elimination through patient's peritoneum and excludes the necessity in applying anticoagulants and expensive "MARS" system.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine.

SUBSTANCE: one should perform the following stages: a) removal of contaminants out of plant; b) plant's reducing; c) treatment of reduced plant with laser radiation; d) suspending the mixture obtained at stage c) in water; e) maceration of suspension obtained at stage d) and f) separation of liquid developed. Composition should be obtained due to this technique. It should be applied at treating hepatitis C as an aqueous extract. It should be applied as aqueous extract as immunostimulant. Pharmaceutical preparation includes aqueous extract as an active constituent.

EFFECT: increased biological activity of the product.

43 cl, 16 ex, 1 tbl

FIELD: medicine, infectology.

SUBSTANCE: one should introduce rhoncoleukin in standard dosages and standard mode in combination with corbiculin for internal intake per 2 g once daily after meals, being pre-dissolved in 50 ml water, at 8-wk-long course. The present innovation enables to decrease the size of liver, favors regression of disease clinical manifestations in shorter period of time and normalization of detoxicational, protein-synthetic, pigment functions of liver and prolonged remission of the disease mentioned due to corbiculin and rhoncoleukin synergism.

EFFECT: higher efficiency of therapy.

3 dwg, 2 ex, 3 tbl

FIELD: medicine and biopharmacology.

SUBSTANCE: claimed biotransplant contains culture of genetically non-modified mesenchyme stem cells (MSC), including fibroblasts of hair follicule dermal papillae, epithelial cells including ones obtained from hair follicle stem niche. Biotransplant is used in intradermal administration. Method for alopecia treatment includes intradermal administration of biotransplant containing from 10 to 100 millions cells to patient, in procedure room by micropapulic method. Biotransplant is administered in physiological solution with concentration from 1 to 10 millions per 1 ml. Total transplant amount is 1-10 millions depending on lesion area and type of alopecia.

EFFECT: method for alopecia treatment with high reproducibility.

12 cl

Up!